Skip to content

8-KAccepted Aug 17, 8:00 AM ET

NRx Pharmaceuticals Reports Q2 2026 Results

NRXPNRX Pharmaceuticals, Inc.

Accepted (ET)

8:00 AM

Aug 17, 2026

Filed

Aug 17, 2026

Documents

14

Size

204.1 KB

Summary

NRx Pharmaceuticals Reports Q2 2026 Results

Updated

What Happened On August 17, 2026, NRx Pharmaceuticals, Inc. announced via press release its results for the second quarter ended June 30, 2026. The company filed a Form 8‑K (Item 2.02) furnishing that press release as an exhibit.

Key Details

  • Form 8‑K filed on August 17, 2026 (Item 2.02: Results of Operations and Financial Condition).
  • Results cover the quarter ended June 30, 2026.
  • Press release furnished as Exhibit 99.1 to the Form 8‑K.
  • Cover Page Interactive Data (Inline XBRL) included as Exhibit 104.

Why It Matters This 8‑K officially notifies investors that NRx has released its quarterly operating and financial results; the press release is the first public summary of those results and is now part of the company’s regulatory record. Retail investors should review the furnished press release for revenue, profit/loss, cash position, or any management commentary, and watch for the forthcoming 10‑Q for full financial statements and more detail.

AI-written summary · check the filing